Founder CEO
Bridge Therapeutics Inc.
The startup develops a novel formulation of buprenorphine-naloxone specifically designed for opioid-experienced patients with chronic pain. This approach enhances pain management by providing a non-addictive alternative that minimizes the risks associated with traditional opioid therapies.
- Biotechnology
Updated 6 months ago
Funding
Raised to date
$11.6MRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Funding rounds are not available yet.
Founders
Product
Features
- The startup develops a novel formulation of buprenorphine-naloxone specifically designed for opioid-experienced patients with chronic pain. This approach enhances pain management by providing a non-addictive alternative that minimizes the risks associated with traditional opioid therapies.